Galectin-3 Overview
Molecule Name
Galectin-3
Synonyms
Galectin-3,LGALS3,MAC2,Gal-3,35 kDa lectin,CBP 35,GALBP,IgE-binding protein,L-31,Laminin-binding protein,Lectin L-29,Mac-2 antigen
Drug Development Progress
Drugs in Clinical Trials7
Approved Drugs1
Highest Development StageApproved
Target Synonym
Galactoside-binding protein，GALBP，Epididymis Secretory Sperm Binding Protein，MAC2，Laminin-binding protein，CBP 35，Gal-3，IgE-binding protein，Carbohydrate-binding protein 35，L-31，Lectin L-29，LGALS3，Advanced Glycation End-Product Receptor 3，Lectin， Galactoside-Binding， Soluble， 3，Galactose-Specific Lectin 3，35 KDa Lectin，Mac-2 Antigen，Galectin-3，LGALS2，CBP35，GALIG，GAL3，L31，Galectin 3，MAC-2
Background
Galectin-3 (Gal-3) is also known as LGALS3, 35 kDa lectin, Carbohydrate-binding protein 35 (CBP 35), Galactose-specific lectin 3, Galactoside-binding protein (GALBP), IgE-binding protein, Laminin-binding protein, Mac-2 antigen, Lectin L-29. Galectin-3 is a member of the lectin family. LGALS3 / Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. LGALS3 / Galectin-3 has been shown to be involved in the following biological processes: cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis.
Galectin-3 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Olitigaltin | GB-0139; TD-139 | Phase 2 Clinical | Lund University Foundation, The University Of Edinburgh | Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis | Details |
| Galactomannan C | GM-CT-01 | Phase 2 Clinical | Galectin Therapeutics Inc | Bile Duct Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Gallbladder Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Prostatic Neoplasms | Details |
| Selvigaltin | GB-1211; GB1211 | Phase 2 Clinical | Galecto Inc | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck | Details |
| ProLectin-M | Phase 2 Clinical | BioXyTran Inc | Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Influenza, Human | Details | |
| Gal-400 | Gal-400 | Phase 1 Clinical | Galecto Inc | Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| Belapectin | GR-MD-02 | Phase 1 Clinical | Galectin Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Esophageal and Gastric Varices; Hepatic Insufficiency; Hypertension, Portal; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Psoriasis; Squamous Cell Carcinoma of Head and Neck | Details |
| SIF-001 | SIF001 | Phase 1 Clinical | Suninflam Inc | Epilepsy; Neuroinflammatory Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ocriplasmin | A-01016; THR-409 | Approved | Thrombogenics | Jetrea, Jejetrea | United States | Vitreomacular Adhesion | Thrombogenics Inc | 2012-10-17 | Arterial Occlusive Diseases; Diabetic macular oedema; Diabetic Retinopathy; Disease Progression; Eye Diseases; Macular Degeneration; Retinal Diseases; Retinal Vein Occlusion; Stroke; Uveitis; Venous Thrombosis; Vitreomacular Adhesion; Vitreous Detachment | Details |